(Source: Actelion Ltd) Market authorization for treatment of pulmonary arterial hypertension granted by European Commission on 12 May 2016 Uptravi available for patients in Germany as of 15 June 2016 FREIBURG, GERMANY and ALLSCHWIL, SWITZERLAND - 15 June 2016 - Actelion (SIX: ATLN) today announced the commercial availability of the oral, selective, IP prostacyclin receptor agonist, Uptravi (selexipag) for the treatment of pulmonary arterial hypertension (PAH) in Germany. Uptravi is indicated for the long-term treatment of pulmonary arterial hypertension (PAH) in adult patients with WHO functional class (FC) II-III, either as combination therapy in patients insufficiently controlled with an...
↧